Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deal Watch: Ionis Out-Licenses Pair Of Generation 2.5 Antisense Candidates

Executive Summary

Janssen and French biotech Dynacure take licenses to antisense candidates arising from Ionis’ Generation 2.5 technology. Merck and Cue sign autoimmune partnership, while Bayer and PeptiDream ink discovery pact.

You may also be interested in...

Dynacure’s Antisense Approach To Rare Myopathies Gets Funding Boost

France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.

PDC Promises: Japanese Startup Fills Pharma’s Pipelines With Peptide-Drug Conjugates

Originated from Tokyo University, drug discovery firm PeptiDream recently competes pre-clinical study for its anti-flu peptide PD-001, after signing 17 deals with large drug makers in 11 years. The company's CEO Patrick Reid outlines to Scrip prospects of peptide-drug conjugates (PDCs) and discovery strategy.

AstraZeneca Aims To Speed Drugs To China Market with New JV

As the Chinese government looks to promote 'made in China' innovation, AstraZeneca has established a joint venture called Dizal Pharmaceuticals in tandem with a well-financed and influential local fund.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts